Royal Bank of Canada’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Royal Bank of Canada’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-281	Closed	-$2K	–	7726
2023 Q3	$2K	Buy	281 +271	+2,710%	+$1.85K	﹤0.01%	6833
2023 Q2	$0	Buy	10 +2	+25%	+$15	﹤0.01%	7779
2023 Q1	$0	Hold	8	–	–	﹤0.01%	7614
2022 Q4	$0	Sell	8 -13	-62%	-$114	﹤0.01%	7874
2022 Q3	$0	Hold	21	–	–	﹤0.01%	8000
2022 Q2	$0	Sell	21 -56	-73%	-$886	﹤0.01%	7832
2022 Q1	$1K	Sell	77 -119	-61%	-$4.12K	﹤0.01%	7637
2021 Q4	$11K	Buy	196 +70	+56%	+$5.24K	﹤0.01%	7033
2021 Q3	$12K	Buy	126 +48	+62%	+$6.4K	﹤0.01%	6910
2021 Q2	$13K	Sell	78 -7	-8%	-$1.19K	﹤0.01%	6783
2021 Q1	$16K	Buy	+85	New	+$21.2K	﹤0.01%	6568

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Royal Bank of Canada's TLIS Position: Q4 2023 in Review

Royal Bank of Canada sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2023, closing a stake of 281 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in TLIS in Q1 2021 and held it in 11 quarters. The position peaked at $16K in Q1 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q4 2023.

Royal Bank of Canada reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2023 after selling out during the quarter.
Royal Bank of Canada sold 281 Talis Biomedical Corporation Common Stock shares in Q4 2023, an estimated $2K.
Royal Bank of Canada first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 11 quarters.
Royal Bank of Canada's Talis Biomedical Corporation Common Stock position peaked at $16K in Q1 2021.
18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2023.

Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.